Manning & Napier Group's BMY Position Overview
Manning & Napier Group (via Manning & Napier Advisors LLC) currently holds 211,054 shares of Bristol-Myers Squibb Company (BMY) worth $9.52 M, representing 0.12% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Manning & Napier Group has maintained a long-term strategic position in BMY, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2016, adding 2.85 M shares. Largest reduction occurred in Q1 2019, reducing 1.22 M shares.
Analysis based on 13F filings available since 2013 Q2
Manning & Napier Group's Bristol-Myers Squibb Company (BMY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Bristol-Myers Squibb Company (BMY) Trades by Manning & Napier Group
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +264,731 | Add 0.00% | 264,730 | $44.68 |
| Q3 2013 | +1,725 | Add 0.65% | 266,455 | $46.27 |
| Q4 2013 | -24,494 | Reduce 9.19% | 241,961 | $53.14 |
| Q1 2014 | -35,092 | Reduce 14.50% | 206,869 | $51.94 |
| Q2 2014 | -206,869 | Sold Out | 206,869 | $0.00 |
| Q4 2016 | +3.06 M | New Buy | 3.06 M | $58.44 |
| Q1 2017 | +176,298 | Add 5.76% | 3.24 M | $54.38 |
| Q2 2017 | -1.2 M | Reduce 37.14% | 2.03 M | $55.72 |
| Q3 2017 | -149,886 | Reduce 7.37% | 1.88 M | $63.74 |
| Q4 2017 | +1.8 M | Add 0.00% | 1.8 M | $61.28 |
| Q1 2018 | -476,091 | Reduce 26.47% | 1.32 M | $63.25 |
| Q2 2018 | +230,707 | Add 17.45% | 1.55 M | $55.34 |
| Q3 2018 | +17,406 | Add 1.12% | 1.57 M | $62.08 |
| Q4 2018 | -6,418 | Reduce 0.41% | 1.56 M | $51.98 |
| Q1 2019 | -1.22 M | Reduce 77.87% | 346,155 | $47.71 |
| Q2 2019 | +123,718 | Add 35.74% | 469,873 | $45.34 |
| Q3 2019 | +2,096 | Add 0.45% | 471,969 | $50.71 |
| Q4 2019 | +32,033 | Add 6.79% | 504,002 | $64.19 |
| Q1 2020 | +88,717 | Add 17.60% | 592,719 | $55.74 |
| Q2 2020 | +33,979 | Add 5.73% | 626,698 | $58.80 |
| Q3 2020 | +5,875 | Add 0.94% | 632,573 | $60.29 |
| Q4 2020 | -43,038 | Reduce 6.80% | 589,535 | $62.03 |
| Q1 2021 | +14,757 | Add 2.50% | 604,292 | $63.13 |
| Q2 2021 | +109,944 | Add 18.19% | 714,236 | $66.82 |
| Q3 2021 | -7,427 | Reduce 1.04% | 706,809 | $59.17 |
| Q4 2021 | -34,139 | Reduce 4.83% | 672,670 | $62.35 |
| Q1 2022 | -48,695 | Reduce 7.24% | 623,975 | $73.03 |
| Q2 2022 | -118,439 | Reduce 18.98% | 505,536 | $77.00 |
| Q3 2022 | -9,245 | Reduce 1.83% | 496,291 | $71.09 |
| Q4 2022 | -4,445 | Reduce 0.90% | 491,846 | $71.95 |
| Q1 2023 | -344 | Reduce 0.07% | 491,502 | $69.31 |
| Q2 2023 | +60,974 | Add 12.41% | 552,476 | $63.95 |
| Q3 2023 | -18,539 | Reduce 3.36% | 533,937 | $58.04 |
| Q4 2023 | -71,686 | Reduce 13.43% | 462,251 | $51.31 |
| Q1 2024 | -36,470 | Reduce 7.89% | 425,781 | $54.23 |
| Q2 2024 | +565,977 | Add 0.00% | 565,976 | $41.53 |
| Q3 2024 | -8,249 | Reduce 1.46% | 557,727 | $51.74 |
| Q4 2024 | -48,363 | Reduce 8.67% | 509,364 | $56.56 |
| Q1 2025 | -34,284 | Reduce 6.73% | 475,080 | $60.99 |
| Q2 2025 | -81,187 | Reduce 17.09% | 393,893 | $46.29 |
| Q3 2025 | -182,839 | Reduce 46.42% | 211,054 | $45.10 |
Manning & Napier Group's Bristol-Myers Squibb Company Investment FAQs
Manning & Napier Group first purchased Bristol-Myers Squibb Company (BMY) in Q2 2013, acquiring 264,730 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Manning & Napier Group has held Bristol-Myers Squibb Company (BMY) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Manning & Napier Group's largest addition to Bristol-Myers Squibb Company (BMY) was in Q4 2016, adding 3,060,280 shares worth $178.84 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Manning & Napier Group's firm, Manning & Napier Advisors LLC, owns 211,054 shares of Bristol-Myers Squibb Company (BMY), valued at approximately $9.52 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Bristol-Myers Squibb Company (BMY) represents approximately 0.12% of Manning & Napier Group's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Manning & Napier Group's peak holding in Bristol-Myers Squibb Company (BMY) was 3,236,578 shares, as reported at the end of Q1 2017. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.